Literature DB >> 2872188

Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat.

T Stålhandske, T Kalland.   

Abstract

Treatment of Sprague-Dawley rats with the compound LS 2616, a quinoline-3-carboxamide, enhanced the delayed-type hypersensitivity response (DTH) to recall antigens as judged by the specific accumulation of inflammatory cells after challenge with Bordetella pertussis in the pleural space. LS 2616 was effective when given both before sensitization and at the time of secondary antigen challenge. The effect of LS 2616 on DTH was dose-dependent. LS 2616 was highly effective in enhancing DTH in rats with suppressed cell-mediated immunity after treatment with anti-thymocyte globulin or prednisolone, indicating its possible value in the immunosuppressed state.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872188     DOI: 10.1016/0162-3109(86)90028-7

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes.

Authors:  C Redondo; I Flores; A Gonzalez; S Nagata; A C Carrera; I Merida; C Martinez-A
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice.

Authors:  J Björk; S Kleinau
Journal:  Agents Actions       Date:  1989-06

4.  Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats.

Authors:  S Kleinau; P Larsson; J Björk; R Holmdahl; L Klareskog
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

5.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Authors:  D J Gross; H Sidi; L Weiss; T Kalland; E Rosenmann; S Slavin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

6.  Stimulation of wound healing by the immunomodulator LS-2616 (Linomide).

Authors:  J Lepistö; M Laato; J Niinikoski; C Lundberg; B Gerdin
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

7.  Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice.

Authors:  R Jonsson; A Tarkowski; K Bäckman
Journal:  Agents Actions       Date:  1988-12

8.  The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo.

Authors:  P Borgström; I P Torres Filho; P Vajkoczy; K Strandgården; J Polaçek; B Hartley-Asp
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.